Search company, investor...

CELLective Dx Corporation

cellectivedx.com

Total Raised

$24.72M

Investors Count

2

Deal Terms

1

Funding, Valuation & Revenue

3 Fundings

CELLective Dx Corporation's latest funding round was a Unattributed VC - II for $5M on October 13, 2008.

CELLective Dx Corporation's valuation in October 2006 was $20.91M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

10/13/2008

Unattributed VC - II

$5M

0

FY undefined

10/5/2007

Unattributed VC

$99M

0

FY undefined

0

10/23/2006

Series A

$99M

$20.91M

0

FY undefined

0

Date

10/13/2008

10/5/2007

10/23/2006

Round

Unattributed VC - II

Unattributed VC

Series A

Amount

$5M

$99M

$99M

Investors

Valuation

$20.91M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

Sources

0

0

This profile has not been claimed.

You're more than your latest funding, tell our customers your company's story.

CELLective Dx Corporation Deal Terms

1 Deal Term

CELLective Dx Corporation's deal structure is available for 1 funding round, including their Series A from October 23, 2006.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

CELLective Dx Corporation Investors

2 Investors

CELLective Dx Corporation has 2 investors. Mohr Davidow Ventures invested in CELLective Dx Corporation's Unattributed VC - II funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

10/23/2006

10/13/2008

3
Series A, Unattributed VC (2007), Unattributed VC - II (2008)

Venture Capital

California

00/00/0000

00/00/0000

Northgate Capital

Subscribe to see more

Diversified Financial Services

California

First funding

10/23/2006

00/00/0000

Last Funding

10/13/2008

00/00/0000

Investor

Northgate Capital

Rounds

3
Series A, Unattributed VC (2007), Unattributed VC - II (2008)

Subscribe to see more

Board Seats

Type

Venture Capital

Diversified Financial Services

Location

California

California

Compare CELLective Dx Corporation to Competitors

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

B
BioMarck Pharmaceuticals

BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.

C
CellXplore

CellXplore is a new, biotechnology company engaged in the development of biomarker-based in vitro diagnostic assays for cancer, initially focusing on breast cancer. Although mammography is an effective screening test for early detection, there is a need for a simple, reliable and sensitive biomarker-based in vitro assay that can be used to stage and characterize breast cancer.nThe company was formed to commercialize groundbreaking discoveries demonstrating up-regulation of the ubiquitin-proteasome pathway in cancerous breast tissue, providing the capability for the noninvasive detection of breast cancer and the ability to monitor the efficacy of chemotherapeutic interventions.nCellXplore's platform technology is not restricted to breast cancer in vitro diagnostics alone, nor is it restricted to cancer diagnostics alone. Beyond cancer, CellXplore is already investigating whether similar blood sample biomarkers can be identified for the early diagnosis of several major debilitating diseases such as muscle wasting, Alzheimer's disease, Parkinson's disease and inflammatory diseases.

E
Emiliem

Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.

A
ARCXIS

ARCXIS develops, produces, and distributes portable biological diagnostic tools with the ability to analyze, detect, and characterize infectious disease agents. It develops diagnostic tools for use in national defense, clinical diagnostics, as well as food and beverage applications. The company was founded in 2004 and is based in Houston, Texas.

P
Proteome Systems

Tyrian Diagnostics is a biotechnology company that specialises in the discovery of biomarkers of disease and in diagnostic test development. The company are building a strong intellectual property portfolio to develop a pipeline of diagnostic products and establishing commercial partnerships to maximise market share and revenue generation from these products. One key avenue for commercialisation is the application of biomarkers to the company's point of need test platform, DiagnostIQTM.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.